Acasti Pharma Presents Preliminary Data Moving Forward With Clinical Strategy

LAVAL, Quebec, March 19, 2013 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti") (TSX-V:APO) (Nasdaq:ACST), a Neptune Technologies & Bioressources Inc. ("Neptune") subsidiary, announces encouraging preliminary clinical data of its "Randomized, Open-Label, Dose-Ranging, Multi-Center Trial to assess the Safety and efficacy of NKPL66 (CaPre®) in the treatment of mild-to-high hypertriglyceridemia" (Open-label). In the course of planning the strategy of its phase III clinical development with CaPre®, Acasti examined triglycerides data from its Open-label clinical trial.